Eliquis 5 mg Once Daily is INCORRECT – The Approved Dose is 5 mg TWICE Daily
Apixaban (Eliquis) for stroke prevention in atrial fibrillation must be dosed at 5 mg twice daily, not once daily. A once-daily regimen of 5 mg provides inadequate anticoagulation and exposes patients to preventable stroke risk.
Correct Dosing for Stroke Prevention in Atrial Fibrillation
Standard Dose
- 5 mg orally twice daily is the approved dose for most patients with nonvalvular atrial fibrillation 1
- This dosing was validated in the ARISTOTLE trial, which demonstrated superiority over warfarin for stroke prevention (HR 0.79,95% CI 0.66-0.95, P=0.01) 2, 1
Dose Reduction Criteria
Reduce to 2.5 mg twice daily only when the patient meets at least 2 of the following 3 criteria 2, 3, 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Critical Dosing Errors to Avoid
Patients with only ONE dose-reduction criterion should receive the full 5 mg twice daily dose. The ARISTOTLE trial included 3,966 patients with a single dose-reduction criterion who safely received 5 mg twice daily, showing consistent efficacy (HR 0.94 for stroke) and safety (HR 0.68 for major bleeding) compared to warfarin 4. These patients had higher baseline stroke and bleeding risk but derived similar relative benefit from the standard dose.
Inappropriate dose reduction is common and harmful. Real-world data show that 61% of patients receiving reduced-dose apixaban do not meet labeling criteria for dose reduction 5. Inappropriately low-dose apixaban is associated with significantly higher mortality (adjusted HR 1.77,95% CI 1.66-1.88) compared to appropriate full-dose therapy 5.
Pharmacokinetic Rationale
Apixaban has a 12-hour half-life and requires twice-daily dosing to maintain therapeutic anticoagulation 6, 7. Once-daily dosing would result in subtherapeutic drug levels for a substantial portion of each 24-hour period, leaving patients vulnerable to thromboembolic events.
Other Approved Indications with Different Dosing
For context, apixaban dosing varies by indication 1:
- DVT/PE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily
- DVT/PE recurrence prevention: 2.5 mg twice daily (after ≥6 months of treatment)
- Post-surgical VTE prophylaxis: 2.5 mg twice daily
The question specifically addresses atrial fibrillation, where 5 mg twice daily is the standard dose.